The burden of out-of-pocket and indirect costs of prostate cancer

Ravishankar Jayadevappa, J. Sanford Schwartz, Sumedha Chhatre, Joseph J Gallo, Alan J. Wein, S. Bruce Malkowicz

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Out-of-pocket and indirect (OPI) costs play an important role in prostate cancer (PCa) outcomes research. We sought to analyze OPI costs of newly diagnosed PCa patients receiving either radical prostatectomy (RP) or external beam radiation therapy (EBRT). METHODS. Prospective cohort design was used to recruit 512 newly diagnosed PCa patients from urology clinics of an urban academic hospital and a Veterans Administration medical center. Participants provided demographic information and completed self-reported generic and prostate-specific Health Related Quality of Life (HRQoL) and indirect-cost surveys at baseline and at 3, 6, 12, and 24 months follow-up. Linear mixed models were applied to study the association between OPI costs, treatment and HRQoL outcomes. Propensity scores adjusted for potential confounders and Bonferroni correction was used to account for multiple testing. RESULTS. Total mean OPI costs varied between RP group and EBRT group at 3-month ($5576 vs. $2010), 6-month ($1776 vs. $2133), 12-month ($757 vs. $774), and at 24-month follow-up ($458 vs. $871). Linear mixed models indicated that RP was associated with lower medication costs (OR = 0.61, CI = 0.48-0.89) and total OPI costs (OR = 0.71, CI = 0.64-0.92). Total OPI costs were inversely related to most of the generic HRQoL items. Similarly, prostate-specific HRQoL items of urinary function (OR = 0.72; adjusted-CI = 0.58-0.84), bowel function (OR = 0.96; adjusted-CI =0.78-0.98), sexual function (OR = 0.85; adjusted-CI = 0.72-0.92), urinary bother (OR = 0.79; adjusted-CI = 0.67-0.83), and sexual bother (OR = 0.88; adjusted-CI = 0.76-0.93) were inversely related to OPI costs. CONCLUSIONS. OPI costs of PCa care are substantial and vary across time and treatment.

Original languageEnglish (US)
Pages (from-to)1255-1264
Number of pages10
JournalProstate
Volume70
Issue number11
DOIs
StatePublished - Aug 1 2010
Externally publishedYes

Fingerprint

Health Expenditures
Prostatic Neoplasms
Prostatectomy
Quality of Life
Prostate
Linear Models
Radiotherapy
Costs and Cost Analysis
Propensity Score
United States Department of Veterans Affairs
Urban Hospitals
Urology
Demography
Outcome Assessment (Health Care)
Therapeutics

Keywords

  • Cost of illness
  • External beam radiation therapy
  • Health related quality of life
  • Indirect cost
  • Prostate cancer
  • Radical prostatectomy

ASJC Scopus subject areas

  • Urology
  • Oncology

Cite this

Jayadevappa, R., Schwartz, J. S., Chhatre, S., Gallo, J. J., Wein, A. J., & Malkowicz, S. B. (2010). The burden of out-of-pocket and indirect costs of prostate cancer. Prostate, 70(11), 1255-1264. https://doi.org/10.1002/pros.21161

The burden of out-of-pocket and indirect costs of prostate cancer. / Jayadevappa, Ravishankar; Schwartz, J. Sanford; Chhatre, Sumedha; Gallo, Joseph J; Wein, Alan J.; Malkowicz, S. Bruce.

In: Prostate, Vol. 70, No. 11, 01.08.2010, p. 1255-1264.

Research output: Contribution to journalArticle

Jayadevappa, R, Schwartz, JS, Chhatre, S, Gallo, JJ, Wein, AJ & Malkowicz, SB 2010, 'The burden of out-of-pocket and indirect costs of prostate cancer', Prostate, vol. 70, no. 11, pp. 1255-1264. https://doi.org/10.1002/pros.21161
Jayadevappa R, Schwartz JS, Chhatre S, Gallo JJ, Wein AJ, Malkowicz SB. The burden of out-of-pocket and indirect costs of prostate cancer. Prostate. 2010 Aug 1;70(11):1255-1264. https://doi.org/10.1002/pros.21161
Jayadevappa, Ravishankar ; Schwartz, J. Sanford ; Chhatre, Sumedha ; Gallo, Joseph J ; Wein, Alan J. ; Malkowicz, S. Bruce. / The burden of out-of-pocket and indirect costs of prostate cancer. In: Prostate. 2010 ; Vol. 70, No. 11. pp. 1255-1264.
@article{df739da82a4342e289401f20e5550d4f,
title = "The burden of out-of-pocket and indirect costs of prostate cancer",
abstract = "BACKGROUND. Out-of-pocket and indirect (OPI) costs play an important role in prostate cancer (PCa) outcomes research. We sought to analyze OPI costs of newly diagnosed PCa patients receiving either radical prostatectomy (RP) or external beam radiation therapy (EBRT). METHODS. Prospective cohort design was used to recruit 512 newly diagnosed PCa patients from urology clinics of an urban academic hospital and a Veterans Administration medical center. Participants provided demographic information and completed self-reported generic and prostate-specific Health Related Quality of Life (HRQoL) and indirect-cost surveys at baseline and at 3, 6, 12, and 24 months follow-up. Linear mixed models were applied to study the association between OPI costs, treatment and HRQoL outcomes. Propensity scores adjusted for potential confounders and Bonferroni correction was used to account for multiple testing. RESULTS. Total mean OPI costs varied between RP group and EBRT group at 3-month ($5576 vs. $2010), 6-month ($1776 vs. $2133), 12-month ($757 vs. $774), and at 24-month follow-up ($458 vs. $871). Linear mixed models indicated that RP was associated with lower medication costs (OR = 0.61, CI = 0.48-0.89) and total OPI costs (OR = 0.71, CI = 0.64-0.92). Total OPI costs were inversely related to most of the generic HRQoL items. Similarly, prostate-specific HRQoL items of urinary function (OR = 0.72; adjusted-CI = 0.58-0.84), bowel function (OR = 0.96; adjusted-CI =0.78-0.98), sexual function (OR = 0.85; adjusted-CI = 0.72-0.92), urinary bother (OR = 0.79; adjusted-CI = 0.67-0.83), and sexual bother (OR = 0.88; adjusted-CI = 0.76-0.93) were inversely related to OPI costs. CONCLUSIONS. OPI costs of PCa care are substantial and vary across time and treatment.",
keywords = "Cost of illness, External beam radiation therapy, Health related quality of life, Indirect cost, Prostate cancer, Radical prostatectomy",
author = "Ravishankar Jayadevappa and Schwartz, {J. Sanford} and Sumedha Chhatre and Gallo, {Joseph J} and Wein, {Alan J.} and Malkowicz, {S. Bruce}",
year = "2010",
month = "8",
day = "1",
doi = "10.1002/pros.21161",
language = "English (US)",
volume = "70",
pages = "1255--1264",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - The burden of out-of-pocket and indirect costs of prostate cancer

AU - Jayadevappa, Ravishankar

AU - Schwartz, J. Sanford

AU - Chhatre, Sumedha

AU - Gallo, Joseph J

AU - Wein, Alan J.

AU - Malkowicz, S. Bruce

PY - 2010/8/1

Y1 - 2010/8/1

N2 - BACKGROUND. Out-of-pocket and indirect (OPI) costs play an important role in prostate cancer (PCa) outcomes research. We sought to analyze OPI costs of newly diagnosed PCa patients receiving either radical prostatectomy (RP) or external beam radiation therapy (EBRT). METHODS. Prospective cohort design was used to recruit 512 newly diagnosed PCa patients from urology clinics of an urban academic hospital and a Veterans Administration medical center. Participants provided demographic information and completed self-reported generic and prostate-specific Health Related Quality of Life (HRQoL) and indirect-cost surveys at baseline and at 3, 6, 12, and 24 months follow-up. Linear mixed models were applied to study the association between OPI costs, treatment and HRQoL outcomes. Propensity scores adjusted for potential confounders and Bonferroni correction was used to account for multiple testing. RESULTS. Total mean OPI costs varied between RP group and EBRT group at 3-month ($5576 vs. $2010), 6-month ($1776 vs. $2133), 12-month ($757 vs. $774), and at 24-month follow-up ($458 vs. $871). Linear mixed models indicated that RP was associated with lower medication costs (OR = 0.61, CI = 0.48-0.89) and total OPI costs (OR = 0.71, CI = 0.64-0.92). Total OPI costs were inversely related to most of the generic HRQoL items. Similarly, prostate-specific HRQoL items of urinary function (OR = 0.72; adjusted-CI = 0.58-0.84), bowel function (OR = 0.96; adjusted-CI =0.78-0.98), sexual function (OR = 0.85; adjusted-CI = 0.72-0.92), urinary bother (OR = 0.79; adjusted-CI = 0.67-0.83), and sexual bother (OR = 0.88; adjusted-CI = 0.76-0.93) were inversely related to OPI costs. CONCLUSIONS. OPI costs of PCa care are substantial and vary across time and treatment.

AB - BACKGROUND. Out-of-pocket and indirect (OPI) costs play an important role in prostate cancer (PCa) outcomes research. We sought to analyze OPI costs of newly diagnosed PCa patients receiving either radical prostatectomy (RP) or external beam radiation therapy (EBRT). METHODS. Prospective cohort design was used to recruit 512 newly diagnosed PCa patients from urology clinics of an urban academic hospital and a Veterans Administration medical center. Participants provided demographic information and completed self-reported generic and prostate-specific Health Related Quality of Life (HRQoL) and indirect-cost surveys at baseline and at 3, 6, 12, and 24 months follow-up. Linear mixed models were applied to study the association between OPI costs, treatment and HRQoL outcomes. Propensity scores adjusted for potential confounders and Bonferroni correction was used to account for multiple testing. RESULTS. Total mean OPI costs varied between RP group and EBRT group at 3-month ($5576 vs. $2010), 6-month ($1776 vs. $2133), 12-month ($757 vs. $774), and at 24-month follow-up ($458 vs. $871). Linear mixed models indicated that RP was associated with lower medication costs (OR = 0.61, CI = 0.48-0.89) and total OPI costs (OR = 0.71, CI = 0.64-0.92). Total OPI costs were inversely related to most of the generic HRQoL items. Similarly, prostate-specific HRQoL items of urinary function (OR = 0.72; adjusted-CI = 0.58-0.84), bowel function (OR = 0.96; adjusted-CI =0.78-0.98), sexual function (OR = 0.85; adjusted-CI = 0.72-0.92), urinary bother (OR = 0.79; adjusted-CI = 0.67-0.83), and sexual bother (OR = 0.88; adjusted-CI = 0.76-0.93) were inversely related to OPI costs. CONCLUSIONS. OPI costs of PCa care are substantial and vary across time and treatment.

KW - Cost of illness

KW - External beam radiation therapy

KW - Health related quality of life

KW - Indirect cost

KW - Prostate cancer

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=77956027853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956027853&partnerID=8YFLogxK

U2 - 10.1002/pros.21161

DO - 10.1002/pros.21161

M3 - Article

C2 - 20658653

AN - SCOPUS:77956027853

VL - 70

SP - 1255

EP - 1264

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 11

ER -